Staging of pancreatic cancer based on the number of positive lymph nodes. BJS 2017; 104: 608-618.
Published: 14th February 2017
Authors: I. Tarantino, R. Warschkow, T. Hackert, B. M. Schmied, M. W. Büchler, O. Strobel et al.
The International Study Group on Pancreatic Surgery has stated that at least 12 lymph nodes should be evaluated for staging of pancreatic cancer. The aim of this population‐based study was to evaluate whether the number of positive lymph nodes refines staging.
Patients who underwent pancreatectomy for stage I–
Some 5036 patients were included, with a median of 18 (i.q.r. 15–24) lymph nodes examined. Positive lymph nodes were found in 3555 patients (70·6 per cent). The median duration of follow‐up was 15 (i.q.r. 8–28) months.
The number of positive lymph nodes in the resection specimen is a prognostic factor in patients with pancreatic cancer.Read more
You may also be interested in
Randomized clinical trial
Randomized clinical trial of laparoscopic ultrasonography before laparoscopic colorectal cancer resection. BJS 2017; 104: 1462-1469.
Authors: S. B. Ellebæk, C. W. Fristrup, C. Hovendal, N. Qvist, L. Bundgaard, S. Salomon et al.
Notes: No additional benefit
Randomized clinical trial
Randomized clinical trial of laparoscopic versus open pancreatoduodenectomy for periampullary tumours. BJS 2017; 104: 1443-1450.
Authors: C. Palanivelu, P. Senthilnathan, S. C. Sabnis, N. S. Babu, S. Srivatsan Gurumurthy, N. Anand Vijai et al.
Notes: Shorter stay
Authors: K. J. Roberts
Authors: B. Le Roy, M. Gelli, G. Pittau, M.‐A. Allard, B. Pereira, B. Serji et al.
Notes: Option to increase resectability
Authors: A. J. Klompenhouwer, M. E. E. Bröker, M. G. J. Thomeer, M. P. Gaspersz, R. A. de Man, J. N. M. IJzermans et al.
Notes: Wait and see policy justified
Nationwide outcomes in patients undergoing surgical exploration without resection for pancreatic cancer. BJS 2017; 104: 1568-1577.
Authors: L. G. M. van der Geest, V. E. P. P. Lemmens, I. H. J. T. de Hingh, C. J. H. M. van Laarhoven, T. L. Bollen, C. Y. Nio et al.
Notes: Negative impacts
Impact of portal vein infiltration and type of venous reconstruction in surgery for borderline resectable pancreatic cancer. BJS 2017; 104: 1539-1548.
Authors: R. Ravikumar, C. Sabin, M. Abu Hilal, A. Al‐Hilli, S. Aroori, G. Bond‐Smith et al.
Notes: No difference between type of reconstruction
Trends in indications, complications and outcomes for venous resection during pancreatoduodenectomy. BJS 2017; 104: 1558-1567.
Authors: D. Kleive, M. A. Sahakyan, A. E. Berstad, C. S. Verbeke, I. P. Gladhaug, B. Edwin et al.
Notes: Severe complications, more reoperations
Authors: R. Green, S. C. Charman, T. Palser
Notes: Variation in compliance related to outcomes
Pancreatoduodenectomy with portal vein resection for distal cholangiocarcinoma. BJS 2017; 104: 1549-1557.
Authors: T. Maeta, T. Ebata, E. Hayashi, T. Kawahara, S. Mizuno, N. Matsumoto et al.
Notes: Poor survival despite portal vein resection
Average treatment effect of hepatic resection versus locoregional therapies for hepatocellular carcinoma.
Authors: A. Cucchetti, V. Mazzaferro, A. D. Pinna, C. Sposito, R. Golfieri, C. Serra et al.
Notes: Resection is better